Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis due to L panamensis in Colombia. This trial is intended to evaluate miltefosine for cutaneous leishmaniasis due to L braziliensis in Bolivia. Patients will be randomly assigned to miltefosine or pentavalent antimony. Standard dose regimens will be used for both drugs.
Epistemonikos ID: 86edcaf3d7b4ae0e11ec76d67de164386b7aa557
First added on: May 04, 2024